These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 10884581)

  • 1. NMR imaging investigations of drug delivery devices using a flow-through USP dissolution apparatus.
    Fyfe CA; Grondey H; Blazek-Welsh AI; Chopra SK; Fahie BJ
    J Control Release; 2000 Jul; 68(1):73-83. PubMed ID: 10884581
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hot-melt extruded ethylcellulose cylinders containing a HPMC-Gelucire core for sustained drug delivery.
    Mehuys E; Vervaet C; Remon JP
    J Control Release; 2004 Feb; 94(2-3):273-80. PubMed ID: 14744479
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effect of wet granulation on the erosion behaviour of an HPMC-lactose tablet, used as a rate-controlling component in a pulsatile drug delivery capsule formulation.
    McConville JT; Ross AC; Chambers AR; Smith G; Florence AJ; Stevens HN
    Eur J Pharm Biopharm; 2004 May; 57(3):541-9. PubMed ID: 15093604
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro evaluation of pectin-HPMC compression coated 5-aminosalicylic acid tablets for colonic delivery.
    Turkoglu M; Ugurlu T
    Eur J Pharm Biopharm; 2002 Jan; 53(1):65-73. PubMed ID: 11777754
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Determination of continuous changes in the gel layer thickness of poly(ethylene oxide) and HPMC tablets undergoing hydration: a texture analysis study.
    Yang L; Johnson B; Fassihi R
    Pharm Res; 1998 Dec; 15(12):1902-6. PubMed ID: 9892476
    [No Abstract]   [Full Text] [Related]  

  • 6. In vitro quantitative ((1))H and ((19))F nuclear magnetic resonance spectroscopy and imaging studies of fluvastatin™ in Lescol® XL tablets in a USP-IV dissolution cell.
    Zhang Q; Gladden L; Avalle P; Mantle M
    J Control Release; 2011 Dec; 156(3):345-54. PubMed ID: 21911016
    [TBL] [Abstract][Full Text] [Related]  

  • 7. NMR microscopy of hydrating hydrophilic matrix pharmaceutical tablets.
    Bowtell R; Sharp JC; Peters A; Mansfield P; Rajabi-Siahboomi AR; Davies MC; Melia CD
    Magn Reson Imaging; 1994; 12(2):361-4. PubMed ID: 8170339
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chronopharmaceutical drug delivery from a pulsatile capsule device based on programmable erosion.
    Ross AC; MacRae RJ; Walther M; Stevens HN
    J Pharm Pharmacol; 2000 Aug; 52(8):903-9. PubMed ID: 11007060
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Once-daily propranolol extended-release tablet dosage form: formulation design and in vitro/in vivo investigation.
    Huang YB; Tsai YH; Yang WC; Chang JS; Wu PC; Takayama K
    Eur J Pharm Biopharm; 2004 Nov; 58(3):607-14. PubMed ID: 15451535
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Influence of enteric citric acid on the release profile of 4-aminopyridine from HPMC matrix tablets.
    Martínez González I; Villafuerte Robles L
    Int J Pharm; 2003 Jan; 251(1-2):183-93. PubMed ID: 12527188
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of a multifunctional matrix drug delivery system surrounded by an impermeable cylinder.
    Krögel I; Bodmeier R
    J Control Release; 1999 Aug; 61(1-2):43-50. PubMed ID: 10469901
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Description of the release of sodium ferulate from hydroxypropyl methylcellulose based matrix tablets in vitro].
    Li FQ; Hu JH
    Yao Xue Xue Bao; 2004 May; 39(5):389-91. PubMed ID: 15338886
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enteric coated HPMC capsules designed to achieve intestinal targeting.
    Cole ET; Scott RA; Connor AL; Wilding IR; Petereit HU; Schminke C; Beckert T; Cadé D
    Int J Pharm; 2002 Jan; 231(1):83-95. PubMed ID: 11719017
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of hydroxypropylmethylcellulose (HPMC) on the release profiles and bioavailability of a poorly water-soluble drug from tablets prepared using macrogol and HPMC.
    Ishikawa T; Watanabe Y; Takayama K; Endo H; Matsumoto M
    Int J Pharm; 2000 Jul; 202(1-2):173-8. PubMed ID: 10915941
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Release of diltiazem chloride and ibuprofen from hydrophilic matrix tablets].
    Vostalová L; Rabisková M; Medvecká G
    Ceska Slov Farm; 2003 Nov; 52(6):295-8. PubMed ID: 14661369
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Poor tolerability of MK-458.
    Cutler NR; Sramek JJ; Block GA
    Arch Neurol; 1993 Sep; 50(9):896. PubMed ID: 8363442
    [No Abstract]   [Full Text] [Related]  

  • 17. Mechanistic Approach to Understanding the Influence of USP Apparatus I and II on Dissolution Kinetics of Tablets with Different Operating Release Mechanisms.
    Lu Z; Fassihi R
    AAPS PharmSciTech; 2017 Feb; 18(2):462-472. PubMed ID: 27106916
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oral mucosal bioadhesive tablets of pectin and HPMC: in vitro and in vivo evaluation.
    Miyazaki S; Kawasaki N; Nakamura T; Iwatsu M; Hou WM; Attwood D
    Int J Pharm; 2000 Aug; 204(1-2):127-32. PubMed ID: 11011995
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of critical formulation and processing variables for metoprolol tartrate extended-release (ER) matrix tablets.
    Rekhi GS; Nellore RV; Hussain AS; Tillman LG; Malinowski HJ; Augsburger LL
    J Control Release; 1999 Jun; 59(3):327-42. PubMed ID: 10332064
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Optimisation of floating matrix tablets and evaluation of their gastric residence time.
    Baumgartner S; Kristl J; Vrecer F; Vodopivec P; Zorko B
    Int J Pharm; 2000 Feb; 195(1-2):125-35. PubMed ID: 10675690
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.